Assessing ADMA Biologics: Insights From 4 Financial Analysts
Portfolio Pulse from Benzinga Insights
ADMA Biologics (NASDAQ:ADMA) has received mixed ratings from 4 analysts over the past three months, with a notable increase in the average 12-month price target to $16.75. Analysts from HC Wainwright, Cantor Fitzgerald, and Mizuho have raised their ratings and price targets, reflecting a positive outlook. The company has shown strong financial performance with significant revenue growth, high net margins, and effective debt management.
August 12, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ADMA Biologics has received mixed ratings from analysts, but the average 12-month price target has increased to $16.75, indicating a positive outlook. Analysts from HC Wainwright, Cantor Fitzgerald, and Mizuho have raised their ratings and price targets.
The increase in the average 12-month price target and raised ratings from multiple analysts suggest a positive short-term impact on ADMA's stock price. The company's strong financial performance further supports this outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100